Factors affecting long-term survival following renal artery stenting
Corresponding Author
Mark C. Bates MD, FACC, FSCAI
Vascular Center of Excellence, Charleston Area Medical Center, Charleston, West Virginia
Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine Charleston Division, Charleston, West Virginia
Department of Surgery, 3100 MacCorkle Avenue SE, Charleston, WV 25304Search for more papers by this authorJohn E. Campbell MD
Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine Charleston Division, Charleston, West Virginia
Search for more papers by this authorPatrick A. Stone MD
West Virginia University School of Medicine, Charleston Division, Charleston, West Virginia
Search for more papers by this authorMichael R. Jaff DO
Harvard Medical School, Boston, Massachusetts
Vascular Medicine, Massachusetts General Hospital, Boston, Massachusetts
Search for more papers by this authorMike Broce BS, Research Associate
Charleston Area Medical Center Research Institute, Outcomes Research Division, Charleston, West Virginia
Search for more papers by this authorPhilip S. Lavigne, Research Assistant
Charleston Area Medical Center Research Institute, Center for Clinical Sciences Research, Charleston, West Virginia
Search for more papers by this authorCorresponding Author
Mark C. Bates MD, FACC, FSCAI
Vascular Center of Excellence, Charleston Area Medical Center, Charleston, West Virginia
Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine Charleston Division, Charleston, West Virginia
Department of Surgery, 3100 MacCorkle Avenue SE, Charleston, WV 25304Search for more papers by this authorJohn E. Campbell MD
Robert C. Byrd Health Sciences Center, West Virginia University School of Medicine Charleston Division, Charleston, West Virginia
Search for more papers by this authorPatrick A. Stone MD
West Virginia University School of Medicine, Charleston Division, Charleston, West Virginia
Search for more papers by this authorMichael R. Jaff DO
Harvard Medical School, Boston, Massachusetts
Vascular Medicine, Massachusetts General Hospital, Boston, Massachusetts
Search for more papers by this authorMike Broce BS, Research Associate
Charleston Area Medical Center Research Institute, Outcomes Research Division, Charleston, West Virginia
Search for more papers by this authorPhilip S. Lavigne, Research Assistant
Charleston Area Medical Center Research Institute, Center for Clinical Sciences Research, Charleston, West Virginia
Search for more papers by this authorAbstract
Introduction: This study defines clinical variables at the time of renal artery stenting that may be predictors of long-term all-cause mortality. Methods: The data are derived from the single operator, single center, renal stent retrospective study (SOCRATES) and includes a review of 748 (336 men, 412 women) consecutive symptomatic patients with de novo atherosclerotic renal artery stenosis treated over an 11-year period. All patients had clinical indications for renal revascularization, including, but not limited to; suboptimal control of hypertension, chronic kidney disease, and cardiac disturbance syndromes. Clinical variables at the time of the index procedure were evaluated as predictors of all-cause mortality using multivariate analysis. Mortality data were derived from hospital records and formal queries of the State Department of Health and Human Services, Health and Vital Statistics Division database. Results: In-hospital, 30-day and 6-month mortality rates were 0.5, 2.0, and 6.3%, respectively. Overall patient survival at years 1, 5, and 10 was 91.2, 66.6, and 40.9%, respectively. Comorbid conditions, including chronic obstructive pulmonary disease and congestive heart failure, were independently associated with increased mortality. There were incremental changes in mortality in patients with baseline azotemia, [preprocedure serum creatinine (sCr) 1.5–2.09 mg/dL hazard ratio 1.52; sCr >2.5 mg/dL hazard ratio 3.39]. Therapy with lipid lowering agents offered a survival advantage (hazard ratio 0.69, P = 0.0.049); however, this study was not designed to evaluate a “protective effect” of lipid lowering medications. Conclusions: Patients with chronic obstructive pulmonary disease and congestive heart failure undergoing renal artery stent revascularization have a poor long-term prognosis. Baseline azotemia is the strongest independent predictor of all cause mortality, with more than 70% of patients with marked azotemia (sCr >2.5) dead at 5 years. © 2007 Wiley-Liss, Inc.
REFERENCES
- 1 Zeller T, Frank U, Muller C, et al. Stent-supported angioplasty of severe atherosclerotic renal artery stenosis preserves renal function and improves blood pressure control: Long-term results from a prospective registry of 456 lesions. J Endovasc Ther 2004; 11: 95–106.
- 2 Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation 1998; 98: 642–647.
- 3 Lederman RJ, Mendelsohn FO, Santos R, et al. Primary renal artery stenting: Characteristics and outcomes after 363 procedures. Am Heart J 2001; 142: 314–323.
- 4 Ramos F, Kotliar C, Alvarez D, et al. Renal function and outcome of PTRA and stenting for atherosclerotic renal artery stenosis. Kidney Int 2003; 63: 276–282.
- 5 Rocha-Singh K, Jaff MR, Rosenfield K. Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: The ASPIRE-2 study. J Am Coll Cardiol 2005; 46: 776–783.
- 6 Bush RL, Najibi S, MacDonald MJ, et al. Endovascular revascularization of renal artery stenosis: Technical and clinical results. J Vasc Surg 2001; 33: 1041–1049.
- 7
Rocha-Singh KJ,
Mishkel GJ,
Katholi RE, et al.
Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis.
Catheter Cardiovasc Interv
1999;
47:
167–172.
10.1002/(SICI)1522-726X(199906)47:2<167::AID-CCD7>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 8 Dorros G, Jaff M, Mathiak L, et al. Multicenter Palmaz stent renal artery stenosis revascularization registry report: Four-year follow-up of 1,058 successful patients. Catheter Cardiovasc Interv 2002; 55: 182–188.
- 9 Watson PS, Hadjipetrou P, Cox SV, et al. Effect of renal artery stenting on renal function and size in patients with atherosclerotic renovascular disease. Circulation 2000; 102: 1671–1677.
- 10 Dorros G, Jaff M, Mathiak L, et al. Renal function and survival after renal artery stent revascularization may be influenced by embolic debris. J Invasive Cardiol 2004; 16: 189–195.
- 11 Harden PN, MacLeod MJ, Rodger RS, et al. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet 1997; 349: 1133–1136.
- 12 Rocha-Singh KJ, Ahuja RK, Sung CH, et al. Long-term renal function preservation after renal artery stenting in patients with progressive ischemic nephropathy. Catheter Cardiovasc Interv 2002; 57: 135–141.
- 13 van de Ven PJ, Beutler JJ, Kaatee R, et al. Transluminal vascular stent for ostial atherosclerotic renal artery stenosis. Lancet 1995; 346: 672–674.
- 14 Beutler JJ, Van Ampting JM, Van De Ven PJ, et al. Long-term effects of arterial stenting on kidney function for patients with ostial atherosclerotic renal artery stenosis and renal insufficiency. J Am Soc Nephrol 2001; 12: 1475–1481.
- 15 Zeller T, Muller C, Frank U, et al. Stent angioplasty of severe atherosclerotic ostial renal artery stenosis in patients with diabetes mellitus and nephrosclerosis. Catheter Cardiovasc Interv 2003; 58: 510–515.
- 16 Rivolta R, Bazzi C, Stradiotti P, et al. Stenting of renal artery stenosis: Is it beneficial in chronic renal failure? J Nephrol 2005; 18: 749–754.
- 17 Tuttle KR, Chouinard RF, Webber JT, et al. Treatment of atherosclerotic ostial renal artery stenosis with the intravascular stent. Am J Kidney Dis 1998; 32: 611–622.
- 18 Olin JW, Melia M, Young JR, et al. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88: 46N–51N.
- 19 Choudhri AH, Cleland JG, Rowlands PC, et al. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ 1990; 301: 1197–1198.
- 20 Buller CE, Nogareda JG, Ramanathan K, et al. The profile of cardiac patients with renal artery stenosis. J Am Coll Cardiol 2004; 43: 1606–1613.
- 21 Aqel RA, Zoghbi GJ, Baldwin SA, et al. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J Hypertens 2003; 21: 1157–1162.
- 22 Edwards MS, Craven TE, Burke GL, et al. Renovascular disease and the risk of adverse coronary events in the elderly: A prospective, population-based study. Arch Intern Med 2005; 165: 207–213.
- 23 Valentine RJ, Clagett GP, Miller GL, et al. The coronary risk of unsuspected renal artery stenosis. J Vasc Surg 1993; 18: 433–439; discussion 439–440.
- 24 Weber-Mzell D, Kotanko P, Schumacher M, et al. Coronary anatomy predicts presence or absence of renal artery stenosis. A prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. Eur Heart J 2002; 23: 1684–1691.
- 25 Missouris CG, Buckenham T, Cappuccio FP, et al. Renal artery stenosis: A common and important problem in patients with peripheral vascular disease. Am J Med 1994; 96: 10–14.
- 26 Schreiber MJ, Pohl MA, Novick AC. The natural history of atherosclerotic and fibrous renal artery disease. Urol Clin North Am 1984; 11: 383–392.
- 27 Baboolal K, Evans C, Moore RH. Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease. Am J Kidney Dis 1998; 31: 971–977.
- 28 Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: Anatomic and renal function changes during drug therapy. Arch Surg 1981; 116: 1408–1415.
- 29 Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659–663.
- 30 Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.
- 31 Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. Am J Kidney Dis 1994; 24: 622–629.
- 32 Bates MC, Rashid M, Campbell JE, et al. Factors influencing the need for target vessel revascularization after renal artery stenting. J Endovasc Ther 2006; 13: 569–577.
- 33 Zierler RE, Bergelin RO, Isaacson JA, et al. Natural history of atherosclerotic renal artery stenosis: A prospective study with duplex ultrasonography. J Vasc Surg 1994; 19: 250–257. discussion 257–258.
- 34 Guzman RP, Zierler RE, Isaacson JA, et al. Renal atrophy and arterial stenosis. A prospective study with duplex ultrasound. Hypertension 1994; 23: 346–350.
- 35 Strandness DEJr. Natural history of renal artery stenosis. Am J Kidney Dis 1994; 24: 630–635.
- 36 Perkovi V, Thomson KR, Becker GJ. Factors affecting outcome after percutaneous renal artery stent insertion. J Nephrol 2002; 15: 649–654.
- 37 Kennedy DJ, Colyer WR, Brewster PS, et al. Renal insufficiency as a predictor of adverse events and mortality after renal artery stent placement. Am J Kidney Dis 2003; 42: 926–935.
- 38 Zeller T, Muller C, Frank U, et al. Survival after stenting of severe atherosclerotic ostial renal artery stenoses. J Endovasc Ther 2003; 10: 539–545.
- 39 Guerrero M, Syed A, Khosla S Survival following renal artery stent revascularization: Four-year follow-up. J Invasive Cardiol 2004; 16: 368–371.
- 40 Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: Prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992; 2: 1608–1616.
- 41 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615–1622.
- 42 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349–1357.
- 43 Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–1307.
- 44 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
- 45 van Domburg RT, Takkenberg JJ, van Herwerden LA, et al. Short-term and 5-year outcome after primary isolated coronary artery bypass graft surgery: Results of risk stratification in a bilocation center. Eur J Cardiothorac Surg 2002; 21: 733–740.
- 46 Leavitt BJ, Ross CS, Spence B, et al. Long-term survival of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery. Circulation 2006; 114( 1 Suppl): I430–I434.
- 47 Selvaraj CL, Gurm HS, Gupta R, et al. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol 2005; 96: 756–759.
- 48 Berger JS, Sanborn TA, Sherman W, et al. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol 2004; 94: 649–651.
- 49 Bates MC, Rashid M, Campbell JE, et al. Factors influencing the need for target vessel revascularization after renal artery stenting. J Endovasc Ther 2006; 13: 569–77.